Profile

Who Is Vanina Popova? Chief Development Officer, GH Research PLC

Popova holds an MD and leads clinical development of GH001 into pivotal programs. GH Research announcement

Organization: GH Research Published: November 15, 2026 Sources: 2 Reviewed by: Dr. Michael Teplitsky

Vanina Popova, MD, is Chief Development Officer at GH Research PLC, where she leads the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement

At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.

Popova spent more than 20 years in global pharmaceutical research and development at Johnson & Johnson. She served as a clinical lead in the Spravato (esketamine) program and led its TRANSFORM-2 trial. GH Research announcement

Where Vanina Popova Is Now

GH Research PLC appointed Popova on November 13, 2026, to lead GH001 clinical development into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement

Career

Popova worked for more than 20 years in global pharmaceutical research and development at Johnson & Johnson. Her neuroscience career there began with 12 years in global clinical operations before she moved into clinical development. GH Research announcement

According to GH Research’s announcement, Popova led TRANSFORM-2, a pivotal Phase 3 trial that supported the approval of Spravato in treatment-resistant depression. She was involved in the early design of an esketamine monotherapy trial and co-authored its publication in JAMA Psychiatry. GH Research announcement

November 2026 Appointment

On November 13, 2026, GH Research PLC announced Popova’s appointment as Chief Development Officer. The announced role covers clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement

What Vanina Popova Leads

Popova will lead the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. She stated that she looks forward to guiding that work. GH Research announcement

Frequently asked questions

Who is Vanina Popova?

Vanina Popova, MD, is Chief Development Officer at GH Research PLC. GH Research announcement

When was Vanina Popova appointed Chief Development Officer?

GH Research appointed her on November 13, 2026. GH Research announcement

What does Vanina Popova lead at GH Research PLC?

She leads the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement

Where did Vanina Popova work before GH Research PLC?

She worked for more than 20 years in global pharmaceutical research and development at Johnson & Johnson. GH Research announcement

What was Vanina Popova’s role in the Spravato program?

She served as a clinical lead in the Spravato (esketamine) program and led TRANSFORM-2. GH Research announcement

Does Vanina Popova hold an MD?

Yes. GH Research’s announcement identifies her as Vanina Popova, MD. GH Research announcement

Sources

  1. markets.businessinsider.com
  2. marketscreener.com

General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Vanina Popova or GH Research. See more people in psychedelic medicine.